Talwar et al 2025 — JACI review of autoimmunity in long COVID

One-paragraph summary

JACI peer-reviewed comprehensive review of B-cell dysregulation and autoantibody production in long COVID (PASC), affecting up to 10% of people recovering from SARS-CoV-2 infection. The review consolidates evidence across multiple proposed pathogenic mechanisms — virus persistence, endotheliitis-and-thrombosis legacy, low-grade tissue-based inflammation / scarring, host virome / microbiome perturbation, and triggering of autoimmunity — with explicit focus on the autoimmunity arm. Several published studies show preexisting and/or de novo autoantibody production after SARS-CoV-2 infection, but the review acknowledges that the persistence of these antibodies and their causal role in long-COVID symptoms remains debated. The authors review the mechanisms through which autoimmune responses arise during and after viral infection, focusing on B-cell dysregulation and autoantibody production in both acute and long COVID. For the project, this paper closes a citation gap — the project's viral-genome-modification framework (white paper §6.4) and B7 bridge (HERV ↔ FM autoimmune via reactivated HERV-W ENV) lean on long-COVID-autoimmunity arguments without a JACI-level peer-reviewed review behind them. Talwar et al provides that grounding. The review's framing of post-viral autoimmunity as plausible-but-debated maps directly onto the project's own confidence-tier discipline: emerging-tier rather than established. The paper does not commit to specific autoantibody panels, leaving the project free to extend the framework with the FM-specific anti-SGC IgG (Goebel 2021) and β2-AR/M3-muscarinic (Oesch-Régeni 2025) axes.

Claims as triples

• viral_infection — bridges → autoantibody_mediated_pain [evidence: review of post-SARS-CoV-2 autoantibody production and B-cell dysregulation; confidence: emerging]
• viral_infection — modulates → IgG_fm [evidence: de novo autoantibody production post-viral; confidence: bridging]
• post_covid_syndrome — bridges → autoantibody_mediated_pain [evidence: PASC-autoimmunity framework; confidence: emerging]
• viral_infection — modulates → fm_autoimmune [evidence: extrapolation from PASC-autoimmunity to FM-autoimmune via shared B-cell-dysregulation framework; confidence: bridging]

Methods note

Narrative review of published primary and review literature on B-cell dysregulation and autoantibody production in acute and long COVID. JACI peer-reviewed. The paper does not perform new primary analysis; it consolidates and frames existing evidence with explicit attention to the persistence and causal-role debate.

Limitations

• Review-tier evidence. No new primary data; the strength of the review is its peer-reviewed JACI venue and the comprehensive framing.
• Authors acknowledge the causal role of autoantibodies in long COVID is debated. This is appropriate epistemic caution; the project should not treat the bridging-tier confidence as a load-bearing claim for FM-specific cure-path planning.
• No FM-specific data. Translation to FM rests on the project's framework that PASC and FM share post-viral autoimmune substrate — a working hypothesis that requires direct demonstration in FM cohorts (Q33, Q39).
• Does not address HERV-driven mechanism. The review focuses on classic B-cell dysregulation pathways (molecular mimicry, bystander activation, epitope spreading); the project's HERV-W-ENV-as-upstream-cause framework is complementary but not addressed in this review.

Open questions raised

• Does the long-COVID-autoimmunity B-cell-dysregulation framework apply to FM-autoimmune subset directly, or does FM require an additional upstream trigger (HERV reactivation, EBV reprogramming, or genetic substrate)?
• Are there long-COVID-specific autoantibody panels (anti-spike, anti-nucleocapsid, others) that overlap with FM-anti-SGC IgG signatures? Cross-cohort serology panel could close B7 bridge at the molecular level.
• Does B-cell-directed therapy (rituximab, daratumumab, FcRn blockers) attenuate long-COVID symptoms preferentially in autoantibody-positive PASC subset? The project's H1-cure-path arms (Fluge & Mella 2025 daratumumab, Shi & Clark 2025 FcRn blockade) make this question testable in PASC cohorts.

Triangulation notes

• Closes a citation gap for the white paper §6.4 (viral-genome-modification upstream layer). The PASC-autoimmunity framing is now backed by a JACI-level peer-reviewed review rather than narrative-level argument.
• Compatible with Bjornevik 2022 EBV→MS framework — both papers describe post-viral autoimmunity emerging from B-cell dysregulation. The two together support the project's working hypothesis that durable post-viral B-cell reprogramming is a foundational driver of multiple post-infectious chronic conditions.
• Reinforces the H1 chain cure-path program. If long-COVID autoimmunity is mechanistically similar to FM-autoimmune subset, the antibody-removal interventional lines (daratumumab, plasmapheresis+IVIG, rituximab, FcRn blockade) generalize across both conditions.
• Compatible with Giménez-Orenga 2025 supplementary data (now reviewed). The observed HERV-W ENV ↔ IFN-γ negative correlation in post-COVID specifically (R=-0.50, p=0.005) may reflect the T-cell-dysregulation arm of the broader B-cell + T-cell post-viral immune-tolerance framework that Talwar et al review.

Bridges

• B7 reinforced — HERV ↔ FM autoimmune via reactivated HERV-W ENV. Talwar et al provides JACI-level framing of post-viral autoimmunity that the HERV-W-ENV-driven version inherits.
• B11 reinforced (MS↔FM via shared EBV-driven plasma-cell reprogramming) — both Bjornevik 2022 and Talwar et al support the post-viral-autoimmunity-as-foundational-driver framework.